Dapagliflozin: BMS 512148; BMS-512148.
Ontology highlight
ABSTRACT: Dapagliflozin, a selective inhibitor of the sodium glucose co-transporter type 2 (SGLT2) is in development for type 2 diabetes mellitus with Bristol-Myers Squibb and AstraZeneca. It is currently undergoing phase III development worldwide with regulatory submissions expected in the second half of 2010. This review looks at the development history and scientific profile of this drug to date.
SUBMITTER:
PROVIDER: S-EPMC3586122 | biostudies-literature |
REPOSITORIES: biostudies-literature
ACCESS DATA